Unresectable hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Japanese Red Cross Society Himeji Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with unresectable HCC in which systemic chemotherapy drug administration treatment was introduced according to the indication criteria described in the drug package insert after the indication was obtained and consent for data analysis was obtained.
Exclusion criteria
Exclusion criteria: Patients who refuse to use clinical data (blood samples, imaging, pathology).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival since induction of systemic therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following data were collected for each regimen: Overall survival, Progression free survival, Time to Progression, post-progression survival, anti-tumor effect, complication frequency, changes in liver reserve and nutritional indices during systemic chemotherapy, changes in tumor markers, changes in physical examination findings, rate of progression to post-progression therapy, and the presence or absence of curative surgery or local therapy after tumor shrinkage and its effect. Clinical data indicators related to life prognosis, treatment response, and occurrence of side effects will be used to construct a treatment selection decision index using AI. | — |
Countries
Japan
Contacts
Public ContactToshifumi Tada
Japanese Red Cross Society Himeji Hospital Internal Medicine
Outcome results
None listed